Pharming Group (XAMS:PHARM) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XAMS:PHARM Pharming Group XAMS:PHARM
80 GF Score
Price €1.17
GF Value €1.28
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group FFO per Share?

FFO per Share only applies to REITs.

XAMS:PHARM
80GF Score
Pharming Group XAMS:PHARM
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pharming Group (XAMS:PHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of €1.17 is trading 8.9% below its estimated GF Value™ of €1.28. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for XAMS:PHARM:

  • FFO per Share:
  • GF Value™: €1.28 vs. price of €1.17 (8.9% below fair value)
  • GF Score™: 80/100 with 1 warning sign

No single metric tells the full story. See the XAMS:PHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
80GF Score

Get the complete analysis for XAMS:PHARM

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.17
Price
€1.28
GF Value